Back to Journals » Cancer Management and Research » Volume 6

Dexrazoxane for the treatment of chemotherapy-related side effects

Authors Langer S

Received 22 April 2014

Accepted for publication 17 July 2014

Published 15 September 2014 Volume 2014:6 Pages 357—363

DOI https://doi.org/10.2147/CMAR.S47238

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Seppo W Langer

Thoracic and Neuroendocrine Section, Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark

Abstract: For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.

Keywords: anthracyclines, cardiomyopathy, extravasation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]